Description: Aeterna Zentaris Inc. a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for oncology and endocrine therapy primarily in Switzerland, the United States, and Japan. It markets Cetrotide, a luteinizing hormone-releasing hormone antagonist treatment for in vitro fertilization. The company's product pipeline includes AEZS-108, which is in Phase III clinical trial for the treatment of endometrial cancer, as well as in Phase II clinical trial to treat triple-negative breast, ovarian, castration and taxane resistant prostate, and refractory bladder cancers; and AEZS-130, an oral diagnostic test that has completed Phase III clinical trial for adult growth hormone deficiency, as well as in Phase IIA clinical trial for the treatment of cancer-induced cachexia. Its product pipeline also comprise Ozarelix, which is in Phase II clinical trial for the treatment of prostate cancer; Perifosine that is in Phase I/II clinical trials for the treatment of neuroblastoma, glioma, and pediatric solid tumors; and AEZS-112 an oral anticancer agent, which has completed Phase I clinical trial for the treatment of solid tumors and lymphoma. In addition, the company's products in preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate for the treatment of prostate cancer; AEZS-129, 134, and 136 PI3K/Erk inhibitors for oncology; and AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.
Home Page: www.zentaris.com
AEZS Technical Analysis
315 Sigma Drive
Summerville,
SC
29486
United States
Phone:
843 900 3223
Officers
| Name | Title |
|---|---|
| Dr. Klaus Paulini Ph.D. | Pres, CEO & Exec. Director |
| Dr. Nicola Ammer M.D. | Chief Medical Officer & Sr. VP of Clinical Devel. |
| Dr. Matthias Gerlach | Sr. VP Manufacturing & Supply Chain |
| Mr. Giuliano La Fratta | Sr. VP of Fin. & CFO |
| Dr. Michael Teifel | Sr. VP of Non-Clinical Devel. & Chief Scientific Officer |
| Dr. Eckhard G. Guenther Ph.D. | Sr. VP of Bus. Devel. & Alliance Management and MD of AEZS Germany |
| Ms. Amélie Métivier | Assistant Sec. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3518 |
| Price-to-Sales TTM: | 4.022 |
| IPO Date: | 1996-07-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |